Compare Applovin Corporation (APP) vs Moderna, Inc. (MRNA) Price & Performance

AppLovin (APP) trades at $313.50, down 7.52% in the last 24 hours, reflecting recent volatility after a Q2 2026 revenue miss. The stock is technically bearish with key support at $306, while fundamentals remain strong with 53% YoY revenue growth, 64.58% net income margin, and robust cash flow. Recent news highlights a Bank of America downgrade to Neutral, citing uncertainty around sustaining 30% long-term revenue growth, contributing to negative sentiment despite strong profitability.

The outlook is mixed: strong fundamentals and an 80.77% analyst buy rating with a $556.53 consensus price target suggest significant upside, but execution risks and growth sustainability concerns pose near-term headwinds. Investors face a trade-off between attractive valuation multiples and potential volatility from competitive and operational challenges in the ad-tech sector.

Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.

Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.